Rate and predictors of success in the retreatment of chronic hepatitis C virus in HIV/hepatitis C Virus coinfected patients with prior nonresponse or relapse.

@article{Labarga2010RateAP,
  title={Rate and predictors of success in the retreatment of chronic hepatitis C virus in HIV/hepatitis C Virus coinfected patients with prior nonresponse or relapse.},
  author={Pablo Labarga and Eugenia Vispo and Pablo Barreiro and Sonia Rodr{\'i}guez-N{\'o}voa and Javier Ara Pinilla and J Antonio Morello and Luz Mart{\'i}n-Carbonero and Paula Tuma and Jos{\'e} Luis Jasso Medrano and Vicente Soriano},
  journal={Journal of acquired immune deficiency syndromes},
  year={2010},
  volume={53 3},
  pages={364-8}
}
BACKGROUND In hepatitis C virus (HCV)/HIV-coinfected patients who failed a course of suboptimal hepatitis C therapy, retreatment with adequate doses and duration of pegylated interferon (pegIFN) plus ribavirin (RBV) is advisable in the presence of compensated advanced liver fibrosis. METHODS The efficacy and safety of pegIFN-alpha2a (180 microg/wk) plus RBV (<75 kg: 1000 mg/d; > or = 75 kg: 1200 mg/d) given for 12 months was prospectively assessed in HIV/HCV patients with nonresponse or… CONTINUE READING

Citations

Publications citing this paper.
Showing 1-10 of 13 extracted citations

Similar Papers

Loading similar papers…